Treatment of hemophilia a with fitusiran
AssigneeGenzyme Corporation
InventorsShauna ANDERSSON, Viridiana Cano, Ekta Seth Chhabra, Sajida Iqbal, Salim Kichou, Barbara Kittner, Laurel Menapace
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for using fitusiran to treat hemophilia A in patients who have previously been treated with emicizumab.
Claims24
A method of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in a human patient having hemophilia A who has been on prophylactic treatment with emicizumab, comprising subcutaneously administering to the human patient in need thereof
- a first dose of fitusiran between about one and about six months after termination of the prophylactical treatment with emicizumab, optionally wherein the first dose of fitusiran is in the amount of about 10 or about 20 mg, and
- subsequent doses of fitusiran in the amount of about 10-80 mg about once a month (QM) or about every four weeks (Q4W), or about once every other month (Q2M) or about once every eight weeks (Q8W).
A method of maintaining an appropriate thrombin generation (AG) potential in a human patient having hemophilia A with or without inhibitors who has been on prophylactic treatment with emicizumab, comprising subcutaneously administering to the human patient in need thereof
- a first dose of fitusiran between about one and about six months after termination of the prophylactical treatment with emicizumab, optionally wherein the first dose of fitusiran is in the amount of about 10 or about 20 mg, and
- subsequent doses of fitusiran in the amount of about 10-80 mg about once a month (QM) or about every four weeks (Q4W), or about once every other month (Q2M) or about once every eight weeks (Q8W).
Fitusiran for use in routine prophylaxis to prevent or reduce the frequency of bleeding episodes characterized in that
- the human patient having hemophilia A has been on prophylactic treatment with emicizumab and
- comprising subcutaneously administering to the human patient in need thereof
- a first dose of fitusiran between one and six months after termination of the prophylactical treatment with emicizumab, optionally wherein the first dose of fitusiran is in the amount of 10 or 20 mg, and
- subsequent doses of fitusiran in the amount of 10-80 mg once a month (QM) or every four weeks (Q4W), or once every other month (Q2M) or once every eight weeks (Q8W).
Fitusiran for use in treatment of hemophilia A characterized in that
- the treatment comprises routine prophylaxis to prevent or reduce the frequency of bleeding episodes,
- the human patient having hemophilia A has been on prophylactic treatment with emicizumab and
- comprising subcutaneously administering to the human patient in need thereof
- a first dose of fitusiran between one and six months after termination of the prophylactical treatment with emicizumab, optionally wherein the first dose of fitusiran is in the amount of 10 or 20 mg, and
- subsequent doses of fitusiran in the amount of 10-80 mg once a month (QM) or every four weeks (Q4W), or once every other month (Q2M) or once every eight weeks (Q8W).
Fitusiran for use in the treatment of hemophilia A with or without inhibitors characterized in that
- the treatment comprises maintaining an appropriate thrombin generation (AG) potential,
- the human patient having hemophilia A has been on prophylactic treatment with emicizumab and
- comprising subcutaneously administering to the human patient in need thereof
- a first dose of fitusiran between one and six months after termination of the prophylactical treatment with emicizumab, optionally wherein the first dose of fitusiran is in the amount of 10 or 20 mg, and
- subsequent doses of fitusiran in the amount of 10-80 mg once a month (QM) or every four weeks (Q4W), or once every other month (Q2M) or once every eight weeks (Q8W).
Dependencies are inferred from the claim text.